Simcere Pharmaceutical Group Limited
SMHGF
$0.6486
-$0.0621-8.74%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 922.57M | 901.19M | 877.93M | 904.26M | 934.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 922.57M | 901.19M | 877.93M | 904.26M | 934.55M |
| Cost of Revenue | 182.21M | 192.03M | 201.45M | 215.00M | 229.57M |
| Gross Profit | 740.36M | 709.16M | 676.48M | 689.26M | 704.98M |
| SG&A Expenses | 421.36M | 400.51M | 378.82M | 390.54M | 404.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -34.66M | -27.04M | -19.34M | -19.86M | -20.47M |
| Total Operating Expenses | 765.03M | 757.48M | 748.31M | 789.33M | 834.05M |
| Operating Income | 157.54M | 143.71M | 129.62M | 114.92M | 100.50M |
| Income Before Tax | 113.92M | -18.38M | -150.46M | -18.77M | 116.63M |
| Income Tax Expenses | 12.06M | 6.93M | 1.79M | 2.82M | 3.92M |
| Earnings from Continuing Operations | 101.87 | -25.31 | -152.25 | -21.59 | 112.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 0.00 | 0.00 | 57.90K | 117.20K |
| Net Income | 101.87M | -25.31M | -152.25M | -21.53M | 112.83M |
| EBIT | 157.54M | 143.71M | 129.62M | 114.92M | 100.50M |
| EBITDA | 188.57M | 174.04M | 159.20M | 144.80M | 130.80M |
| EPS Basic | 0.04 | -0.01 | -0.06 | -0.01 | 0.04 |
| Normalized Basic EPS | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 |
| EPS Diluted | 0.04 | -0.01 | -0.06 | -0.01 | 0.04 |
| Normalized Diluted EPS | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 |
| Average Basic Shares Outstanding | 10.05B | 10.18B | 10.30B | 10.37B | 10.43B |
| Average Diluted Shares Outstanding | 10.08B | 10.19B | 10.30B | 10.38B | 10.46B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 54.92% | -225.47% | -38.08% | -269.21% | 51.38% |